| Product Code: ETC8452907 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Overview |
3.1 Myanmar Country Macro Economic Indicators |
3.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, 2021 & 2031F |
3.3 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market - Industry Life Cycle |
3.4 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market - Porter's Five Forces |
3.5 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Brands, 2021 & 2031F |
4 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Myanmar |
4.2.2 Growing awareness about the benefits of GLP-1 agonists in managing diabetes |
4.2.3 Favorable government initiatives towards improving healthcare infrastructure in Myanmar |
4.3 Market Restraints |
4.3.1 Limited access to healthcare facilities in rural areas of Myanmar |
4.3.2 High cost associated with GLP-1 agonist medications |
4.3.3 Lack of trained healthcare professionals to prescribe and administer GLP-1 agonists |
5 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Trends |
6 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market, By Types |
6.1 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Dulaglutide, 2021- 2031F |
6.1.4 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Exenatide, 2021- 2031F |
6.1.5 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Liraglutide, 2021- 2031F |
6.1.6 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lixisenatide, 2021- 2031F |
6.1.7 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Semaglutide, 2021- 2031F |
6.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market, By Brands |
6.2.1 Overview and Analysis |
6.2.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Byetta, 2021- 2031F |
6.2.3 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Bydureon, 2021- 2031F |
6.2.4 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Victoza, 2021- 2031F |
6.2.5 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Trulicity, 2021- 2031F |
6.2.6 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lyxumia, 2021- 2031F |
6.2.7 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Ozempic, 2021- 2031F |
7 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Import-Export Trade Statistics |
7.1 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Export to Major Countries |
7.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Imports from Major Countries |
8 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Key Performance Indicators |
8.1 Number of diabetes cases diagnosed annually in Myanmar |
8.2 Percentage increase in prescription of GLP-1 agonists by healthcare providers |
8.3 Investment in healthcare infrastructure development in Myanmar |
9 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market - Opportunity Assessment |
9.1 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Brands, 2021 & 2031F |
10 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market - Competitive Landscape |
10.1 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Revenue Share, By Companies, 2024 |
10.2 Myanmar Glucagon like Peptide 1 (GLP 1) Agonists Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here